These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 35718266)

  • 1. In vitro susceptibilities of isolates of potentially naturally inducible chromosomal AmpC-producing metallo-β-lactamase-negative carbapenem-resistant Enterobacterales species to ceftazidime-avibactam: Data from the Antimicrobial Testing Leadership and Surveillance Programme, 2012-2019.
    Jean SS; Lee YL; Hsu CW; Hsueh PR
    Int J Antimicrob Agents; 2022 Sep; 60(3):106617. PubMed ID: 35718266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
    Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
    Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
    Piérard D; Stone GG
    BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020.
    Lee YL; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2022; 60(5-6):106679. PubMed ID: 36241011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of Ceftazidime-Avibactam and its comparators against Carbapenem resistant Enterobacterales collected across India: results from ATLAS surveillance 2018 to 2019.
    Bakthavatchalam YD; Routray A; Mane A; Kamat S; Gupta A; Bari AK; Rohit A; Poojary A; Mukherjee DN; Sethuraman N; Munshi N; Shah S; Balaji V; Gupta Y
    Diagn Microbiol Infect Dis; 2022 May; 103(1):115652. PubMed ID: 35255290
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Karlowsky JA; Hackel MA; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2023 Jan; 67(1):e0134622. PubMed ID: 36602322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Ceftazidime-Avibactam 30/20-μg Disk, Etest versus Broth Microdilution Results When Tested against
    Han R; Yang X; Yang Y; Guo Y; Yin D; Ding L; Wu S; Zhu D; Hu F
    Microbiol Spectr; 2022 Feb; 10(1):e0109221. PubMed ID: 35019685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of aztreonam/avibactam and ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance.
    Mushtaq S; Vickers A; Woodford N; Livermore DM
    Int J Antimicrob Agents; 2024 Mar; 63(3):107081. PubMed ID: 38176458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017-2019.
    Karlowsky JA; Kazmierczak KM; Valente MLNF; Luengas EL; Baudrit M; Quintana A; Irani P; Stone GG; Sahm DF
    Braz J Infect Dis; 2021; 25(6):101647. PubMed ID: 34774471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of the Italian infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-IT): activity of ceftazidime/avibactam against Enterobacterales isolated from urine.
    Giani T; Antonelli A; Sennati S; Di Pilato V; Chiarelli A; Cannatelli A; Gatsch C; Luzzaro F; Spanu T; Stefani S; Rossolini GM
    J Antimicrob Chemother; 2020 Apr; 75(4):979-983. PubMed ID: 31958125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula.
    Sonnevend Á; Ghazawi A; Darwish D; Barathan G; Hashmey R; Ashraf T; Rizvi TA; Pál T
    Int J Infect Dis; 2020 Oct; 99():253-259. PubMed ID: 32738488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is Ceftazidime/Avibactam an Option for Serious Infections Due to Extended-Spectrum-β-Lactamase- and AmpC-Producing
    Isler B; Ezure Y; Romero JLG; Harris P; Stewart AG; Paterson DL
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33046493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against Pathogens Harboring OXA-48 and AmpC Alone or in Combination with Other β-Lactamases Collected from Phase 3 Clinical Trials and an International Surveillance Program.
    Lin LY; Debabov D; Chang W; Stone G; Riccobene T
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0198521. PubMed ID: 35225651
    [No Abstract]   [Full Text] [Related]  

  • 15. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.
    Karlowsky JA; Biedenbach DJ; Kazmierczak KM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2016 May; 60(5):2849-57. PubMed ID: 26926635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021.
    Wise MG; Karlowsky JA; Mohamed N; Kamat S; Sahm DF
    Eur J Clin Microbiol Infect Dis; 2023 Sep; 42(9):1135-1143. PubMed ID: 37526796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in
    Kawai A; McElheny CL; Iovleva A; Kline EG; Sluis-Cremer N; Shields RK; Doi Y
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32284381
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In Vitro Activity of Ceftazidime-avibactam and Colistin Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates].
    Hoşbul T; Aydoğan CN; Kaya S; Bedir O; Gümral R; Albay A
    Mikrobiyol Bul; 2022 Apr; 56(2):218-229. PubMed ID: 35477226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coli.
    Livermore DM; Mushtaq S; Vickers A; Woodford N
    Int J Antimicrob Agents; 2023 May; 61(5):106776. PubMed ID: 36893810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.